Manufacturing API, Drugs, and Excipients in America Act of 2020 or the MADE in America Act of 2020 This bill establishes a tax credit for taxpayers engaged in medical production activities in certain areas and contains other provisions related to pharmaceuticals. An eligible taxpayer may claim a tax credit equal to 30% of qualified expenditures related to the production of pharmaceuticals, medical devices, or other related items in a designated qualified opportunity zone with a poverty rate higher than 30%. In addition, the Food and Drug Administration shall continue a program to evaluate new drug manufacturing technologies included in an application for approval of a drug or biological product. The bill imposes various requirements on this program, including deadlines for evaluating such a technology. Furthermore, the Department of Health and Human Services shall establish or expand programs to promote regulatory consistency and cooperation with drug regulatory authorities in other countries.